<SEC-DOCUMENT>0001213900-15-000744.txt : 20150205
<SEC-HEADER>0001213900-15-000744.hdr.sgml : 20150205
<ACCEPTANCE-DATETIME>20150205172148
ACCESSION NUMBER:		0001213900-15-000744
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150205
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150205
DATE AS OF CHANGE:		20150205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		15581169

	BUSINESS ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k020515_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-family: Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-family: Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pursuant
to Section 13 or 15(d) of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Securities
Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date
of Report (Date of earliest event reported): February 5, 2015</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding: 0; text-align: center; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Delaware</B></FONT></td>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding: 0; text-align: center; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>000-52446</B></FONT></td>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding: 0; text-align: center; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>88-0378336</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(State
        or other jurisdiction</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">of&nbsp;incorporation)</FONT></P></td>
    <TD STYLE="padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Commission</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">File
        Number)</FONT></P></td>
    <TD STYLE="padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(IRS
        Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Identification
        No.)</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>546
        Fifth Avenue, 14th Floor</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>New
        York, NY</B></FONT></P></td>
    <TD STYLE="vertical-align: top; width: 2%; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; padding: 0; text-align: center; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>10036</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address
    of principal executive offices)</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Zip
    Code)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registrant&rsquo;s
telephone number, including area code: <B>(646) 459-4201</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; padding: 0; text-align: center; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>N/A</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Former
    name or former address, if changed since last report)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<U>see</U> General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; text-align: center; padding: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</FONT></td>
    <TD STYLE="width: 94%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; text-align: center; padding: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</FONT></td>
    <TD STYLE="width: 94%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; text-align: center; padding: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</FONT></td>
    <TD STYLE="width: 94%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; text-align: center; padding: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</FONT></td>
    <TD STYLE="width: 94%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
8.01 Other Events.</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actinium
Pharmaceuticals, Inc. issued a press release on February 5, 2015 announcing a proposed public offering of its common stock and
warrants. A copy of the release is attached to this Form 8-K as Exhibit&nbsp;99.1.</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
9.01 Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(d)</I></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Exhibits. </I></FONT><FONT STYLE="font: 7pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 3%; background-color: White">&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0; width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit&nbsp;99.1</FONT></td>
    <TD STYLE="padding: 0; font: 7pt Times New Roman, Times, Serif; text-indent: 0; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0; width: 87%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press
    release of Actinium Pharmaceuticals, Inc. dated February 5, 2015</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    February 5, 2015</FONT></td>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ACTINIUM
    PHARMACEUTICALS, INC.</B></FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 60%; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 4%; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 35%; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 1%; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding: 0 0 1.5pt; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding: 0 0 1.5pt; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></td>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Kaushik J. Dave&nbsp;</I></FONT></td>
    <TD STYLE="vertical-align: bottom; padding: 0 0 1.5pt; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;&nbsp;Kaushik
        J. Dave</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</FONT></P></td>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0.3"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k020515ex99i_actiniumph.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.95pt 0 0; text-align: center; color: Red"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 18pt/19.45pt Times New Roman, Times, Serif; margin: 0 0.9pt 0 0; text-align: center"><FONT STYLE="color: #424241"><B>Actinium<FONT STYLE="letter-spacing: -0.4pt">
</FONT>Pharmaceuticals,<FONT STYLE="letter-spacing: 1.1pt"> </FONT>I<FONT STYLE="letter-spacing: -0.2pt">n</FONT></B></FONT><B><FONT STYLE="color: #2A2828; letter-spacing: 0.2pt">c</FONT><FONT STYLE="color: #424241">.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Actinium Announces Proposed Public Offering
of Common Stock and Warrants to Purchase Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NEW YORK, NY, February
5, 2014<FONT STYLE="color: red"> </FONT></B>&ndash; Actinium Pharmaceuticals, Inc. (&ldquo;Actinium&rdquo; or the &ldquo;Company&rdquo;)
(NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced
cancers, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock
in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional
15 percent (15%) of the number of shares of common stock and warrants sold in the offering solely to cover over-allotments, if
any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may
be completed, or as to the actual size or terms of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Laidlaw &amp; Company
(UK) Ltd. acted as sole book-running manager for the offering. MLV&amp; Co. acted as co-manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The offering is being conducted pursuant
to a shelf registration statement that was previously filed with, and declared effective by, the U.S. Securities and Exchange
Commission (&quot;SEC&quot;). Prospective investors should read in their entirety the prospectus supplement and the
accompanying prospectus and the other documents that Actinium has filed with the SEC for more complete information about
Actinium and the offering. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be
filed with the SEC and will be available free of charge on the website of the SEC at www.sec.gov. When available, electronic
copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained from the offices of
Laidlaw &amp; Company (UK) Ltd., <FONT STYLE="background-color: #FEFEFE">546 Fifth Avenue, 5<SUP>th</SUP> Floor, New York,
NY, 10036, telephone: 212-953-4900</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B>About Actinium Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com)
is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced
cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization
of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies.
The Company's lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing patients for hematopoietic stem cell transplant,
commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study
of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The
Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients
over the age of 60 in a single-arm multicenter trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B>Forward-Looking Statement for Actinium
Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">This news release contains &quot;forward-looking
statements&quot; as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's
current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth
in the statements. The forward-looking statements may include statements regarding product development, product potential or financial
performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events
or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Contact:</B><BR>
<BR>
Actinium Pharmaceuticals, Inc.<BR>
Evan Smith, CFA<BR>
VP Investor Relations and Finance<BR>
(646) 840-5442<BR>
esmith@actiniumpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!&`'L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBC-``3BF&5=F3T'))[5\,_\`!2;_`(+4>'_V/]:O_`W@BQM_&/Q,ME'VF&8N
MFFZ,2`<3.O,DN&4^5'TW`NR\`_DM\<_VY_BY^U%J=WJ'CGX@>);BT:91_9]E
M<M9:3:]=B"WBQ'U'!?>YY!-*X[=S^B^3XN>%(I&1O$OA]74[2IU&$$'T^]UK
M9TW5K76;".ZM)H;JUF&Z.:%UDC<>H8$@BOY=X/@;XCUO2/[3TCP#XIU.TF9B
M;JTT"YFB8C.X^8L)W@#J0W?J*O?#;XT>*_@=J_VOP?XK\3>#[[3W/EIIFI/:
M/""!A&A8%2@(/RNI5CR12Y@T/Z@U(/2AVVK7Y-?\$_O^#A&XDU[3/!WQY^R#
M[?*L%MXPLH1#';LV`JW\"\("2!YR8`S\R*`6K])_VAOVCO"W[,GP;U3QQXKU
M%+;0]-A$@,1#RWCM_JXH5S\[N<!0/KTR:VH4:E:I&C1BY2D[)+5MO9&5:M"C
M3=6J[16K;V2,+]L7]K[PK^Q?\&[OQ=XGD>7YOL^FZ=`1]IU6Z()6&,=NA+,>
M%4$GT/S?_P`$OO\`@JW=?M:^--1\!>/+"'2O'!>XU#2FM(&6UOK,'?Y1'59(
MD(&YL"1<-P<BOS-_:,_:*^(?_!2K]I2*_>UN+Z[U&==*\-^%[24LM@DA)2).
M-A<JN^64X[G(5>,_X@?&.R_9ULCX!^%OB*(>)+:^CE\8>-M.D93JE[`P=;"P
ME&!]@MYP-S#_`(^)$R?W:J#^OY[PEE'#G#WLLT]_'5K.*3^"WZ=W]IZ+:Y^7
MY/Q)FF>9XI9=[N$I:2;7Q7_7MV6KWL?T51')XJ2OD7_@D3_P43OOV^O@I>G7
M](GL/&/@\PV>LWD$!73=3=U)2:%NBR%5S)%_`6&/E85]<KTK\;6Q^J;:"T44
M4P"D9L4M,=L.*`/'=>_X*&?`_P`+ZW>Z;J/Q3\$6E_IL[6MU;R:I&)+>56*L
MC#/!#`@^A%>#_P#!0;_@KAX(^&W[,>N3?"?QMX5\4>/M37[!I:6E^DHTXR`[
M[QP#TB0$J/XI"BX.37Q#^T#_`,$@/BUXX^.WC?6;75_ADECJWB&_O[6*?Q2D
M;K'+=22`.A3Y6PQR,\'-?,7[3?[*7B7]DCQSIFC>*[_P_<7.I69U"*71=2^W
M6X0.5PSA1L;*_=^AS7[KA/#[A&I2A.>9V;2;7NZ-K5;'Y'B>->)*=2489?=)
MM)ZZ^9P>C^$M=\?>+[2*XU?3H-0U>?$VHZKJ82V$TC_O)KF8DLH/WV<@G/;.
M!7ZX_L-?#C]C?]CGPOIUUJ/Q'^'OC?Q^P$UYX@U*=9L3$<BUA(*PH,8!`W\9
M9L]/SA_9:_8E\7_MAIJLGAK4?"T*>'S`EQ+K>J'3_.$@?;Y9=/WFP(0=O0D9
MZUZT/^",GQ?PQ;Q)\)BQ()9?%J<=/5.W&*UEX><&I_\`(T?_`)+_`)&"XWXG
M:O\`V??_`,"/UJD_X*??L^V]M&[?%SP:(G!VD7G7!P>@KA_']G^RQ_P5-DN/
M"IU3PAXS\10V<LUO>:6_E:OIL8PC30SA0PVEUX.5.1E2*_,[4?\`@C1\4;=$
M0>)?A$R*`%,GC"->>I(_==-Q)KZ>_P""/_\`P3Y\<?LQ_M<77B3Q)K/P\OK)
MO#UU9"'1?$"WUR'DEA8$QA%.W"G+>I%>/GO!?"V$RZKB<'F#J58KW8Z:O[CU
M,GXLX@Q.-IT,5@N2G)V<M=$?GS_P4%_8!\6?L!?%Z7PWK2R:OX=U-99O#7B"
M.';'JL/=)<?*EPF[#H>V&4[37J7[)/Q^LOVN?@O:_LX?%SQ`;5=+D-S\./%E
M_.(X=`U!(G1=/NW8@36S@LB,063<$_N$?M?^U9^RUX1_;#^"VI^!_&5C]ITV
M_'F0SQG9<Z;<*#Y=Q"_59$)..Q!*G()!_G5_:O\`V;=8_92^/7B'P#XANK;5
M;WP_*(TO]/??;7$;`/$^,_))M9=\;9*MQ@\&OR7`XZO@\1#%X67+.#337<_1
M\7A*6)H2P]=7A)6:\F>K?$;Q#IO[(7AG4OAUX?U[2]6^+.M%]/\`&VOZ:[36
MN@VI4B31[&<`?O6P%N)U`)!,2G`?/)?L._L1^)?V\_C5!X-\*VRZ7H4"+-X@
MUI8V:/1;9CC!W!=\K;"(T_B;DG:K5P/[/WP+U/\`:/\`C'X7\":)>Z=I>H^)
M[T6MM<ZE)]F@#$LQ)/5CMWG8"2S;5')%?T8_L8_L>^$_V(_@A8>"_"Z2S*C&
MYU+4KGFZU>[8`27$I]3C`4<*H"C@5T9MG&+S3%RQN.ES3E^'9)=$NB1AEF5X
M;+L-'"82/+"/]7?F=)^SQ^SWX7_9>^$FC>"_"&GII^BZ-"(T&!YMPY^_-*P`
MWRN?F9CU)],"NWHHKSSO"BBB@`IK'#"G4A&:`/P2_:3_`."7?Q^\:?M'^/\`
M6=-^%'B"]T_5O$NI7=I<B6T*30R74KQNH:;.&5@>0.O05Y/\8?V$/B]^SUX)
MN/$GC7P1J'A'P_;.D/VS4;RRBC9WX5`%E+,YYPJ@G\LC^D78/0?E7EO[97[*
M/A_]M+]GGQ#\/O$2^7;ZQ;G[)>H@:;2[I>8;F//\2/@]LC(Z$U^U8;QRSFA2
MA2C0I6BDMI]%;^<_+*_A+E=6I*K*K4O)M[QZ_P#;I_.3X'\!ZC\1O$VE>&=)
M%OJFLZG,MO8VC7UN#/,_W8HB[A`S'MD$DCCFO:E_X).?M#1O_P`D:\2A4&U<
M369+#D?\]L#'X]:\4_:?_9D\5_L?_%F^\">-=*^P:Y:/YD%S$[+!?0*<1WEL
MY`W1MM!^4[D9<':17WY^PM_P<*:U\/-`M_#'QET+4O%=OIT$45MXAT95DU`(
M%`"W,1*K*V!GS`RL><J6R:U?CSG3?\"E]T__`),A>$.5?\_JGWQ_^1/FU/\`
M@DG^T(,Y^#OB%RRG>Y:S#$\=O.Q_^JOKK_@B[^PI\5/V<?VPYO$/C/X>:OX7
MT=O#5W9F\G>W\HSM+`P7$<C$Y"MC(XQ[U]4>'_\`@NC^S#K?AD:BWQ$-B?*$
MK6MUHMZERF<`KL$1W,,\[2>AP2.:\&_:L_X.,_!N@>&;NR^#N@ZCXHUF0F*#
M6=9M6LM*M>1^\$9(GEX.0I5`>YQQ7DYYXP9KFF`JY?6HTXQJ*S:4K_*\V=^5
M>&67X#&4\93JS<H.Z3:M\]#U3_@KO_P54M?V+O"__"$^#FBU+XJ^(;0O"%=6
MC\.6S_+]KF')\SDF./'."S84?-^)?PY^'7C3]J/X\:5X6T!)O$OBWQ7<81Y2
M9&NV=BT]U<3')15P9'<D@#'0D"K.H/XG_:5^+LEP\>L>,O&WC2_61O*'G7FK
MW4S8*K@#:!M7:"-B*.<*,5^D_C/_`()9?$']@C_@G+KUY\.9K6_^)GB*(-X^
MU&S1FU&/21\S6.FLOW8TX,I&&E"L1CY5'YGE>`^NXVEA'-0YVES2T2OU9]YF
M&,6%PM3$*+ERINRW=C\U_CS\%]5_9R^*5[X=\17<:W=I'#>6EUI5T9;34+?E
MDO+.XC(WQL0VUA@B0;2%93C]>?\`@B]_P5O7]I32++X5_$K5$;XD:=`?[*U:
M:1`OBJW09.2./M<:XWKU<#>.=V/R]^&OB[PU\1OAM%\-/'UPECX8^T/=>&O$
MC1&4^#K]V&Y_E^9M.F/,\(^Z2)4&X$-P'BSX4^)O@C\5;G1;]&\.^*/#%PMU
M'=6EP(Q;2KB6*ZMKE2H:-QLDCF0_,K`@=17O\:<'8SA['/#5_>A*[A.VDE_\
MDNJOY[,\;A?BC#9WA?;T=)KXH]4_\NQ_4L#FEKXY_P"".O\`P4.U+]N?X,WE
MCXFTVZB\8^"$@M-5U.)=^GZR'4^7<(Z@*LS!#YD7\)^8?*PQ]C5\GN?2!111
M0`4444`%(1FEHH`\M_:O_8U^'?[:7P[/ASX@Z!!JUM$6>SNT/DWVF2,,&2WG
M'SQL1C.#A@,$$5^7?QP_X-L/'7@N^O)OA;X\TG7M%W&2'3M:#V&I;,?ZHS1@
MP2GC`+)&.>:_9:B@#^?%O^"*W[36F:O]AD^%JSF238ES:^(++[+'DY#DF4'Z
M\?A7I/PA_P"#>/X[>-KYO^$LU3P;X*LD?#-)=-J4\HQP5CAPO?H9%''W3UK]
MQ:*0'S/^PC_P2O\`AG^PC"=1T2WGU_QG<0?9[KQ)J0#73(<;HX4'RP1G`R$Y
M/\3-@5]*/"`O7&*DH/(I@?CY_P`%E_\`@E:/A/J-_P#%WX<:7_Q2UU,USXFT
MBV@W'1Y'8LUY"HY\AF.9%'W#\P^4G;\]?L6_!'4?^"A5UI'PCNX+\W7AJ/[9
MI'BV&W2Z_P"$;L-^Z>QN@SKYMG*3^Y4'?%,<J"C.!_0!>Z=%J-K)!/''-!.C
M1RQR(&216&"K`\$$9!%>??LX?LE^`_V2_#&HZ1X!T&VT&RU6_EU&Z$>7>65V
M)P68EMB`[43.$48%?IS\0UBN&YY)FE+VM2-O9S;^'S?6\>G=:/S_`#]<$O#Y
M[#-<OJ>S@[\\>_DO)]>W0F_9A_9H\(?LD?!_2O`_@K3(],T;2TR3UFO9F_UE
MQ,_5Y7/))^@P``/0^E-1-G?-.K\Q1^@!1110`4444`%%%%`!1110`4444`%%
1%%`!1110`4444`%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
